FDA Committee Advises Against Compounding Unapproved Peptides

The FDA's Pharmacy Compounding Advisory Committee recently recommended not to include seven unapproved peptides on the agency's 503A Bulks List. This decision was based on concerns regarding minimal human data and potential safety signals. Despite some political pressure for broader access, the committee prioritized patient safety in its assessment.